Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tecentriq Data Builds As IMpower132 In NSCLC Meets PFS Co-Primary Endpoint

Executive Summary

As Roche keeps building its catalog of positive Tecentriq results, its Phase III IMpower132 study meets PFS endpoint in NSCLC, with OS data coming later.

You may also be interested in...



IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC

The lack of significant overall survival benefit in IMpower132 may be related to PD-L1 expression – though the dataset is incomplete – or the higher dose of chemo used in the trial.

Bristol Touts Opdivo's Stability – And Diversity – In Strong Q2

The recently launched Opdivo/Yervoy combination already has a leading position in first-line kidney cancer in the US – with a 30% share of new patients – but has been rejected in Europe.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel